IDXX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IDEXX Laboratories Inc is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has shown strong financial performance and has positive growth trends, the technical indicators and options data do not suggest a compelling entry point currently. Additionally, mixed analyst ratings and lack of significant recent catalysts make it prudent to hold off on investing in this stock right now.
The MACD is above 0 and positively contracting, indicating a mild bullish trend. However, the RSI is neutral at 43.544, and moving averages are converging, showing no clear direction. The stock is trading below the pivot point of 577.131, with key support at 555.258 and resistance at 599.005, suggesting limited upward momentum.
Hedge funds are significantly increasing their positions in the stock, with a 764.05% increase in buying over the last quarter.
IDEXX launched a canine cancer detection panel in the UK, which could drive future growth in the veterinary diagnostics segment.
Strong financial performance in Q4 2025, with revenue, net income, and EPS showing double-digit YoY growth.
Mixed analyst ratings with multiple price target reductions, reflecting concerns over macroeconomic headwinds and slower growth in key segments.
The stock has a 90% chance of declining slightly (-0.36%) in the next day and -1.12% in the next month, based on historical candlestick patterns.
No significant insider or congress trading activity to indicate strong confidence from influential figures.
In Q4 2025, IDEXX Laboratories reported a 14.28% YoY increase in revenue to $1.09 billion, a 14.82% YoY increase in net income to $248.19 million, and a 17.56% YoY increase in EPS to $3.08. Gross margin also improved slightly to 60.35%, up 0.92% YoY, indicating strong operational efficiency.
Analyst ratings are mixed. Citi initiated coverage with a Neutral rating and a $650 price target, citing macroeconomic pressures. Stifel, Piper Sandler, UBS, and Barclays have all lowered their price targets recently, citing concerns about muted growth and macro headwinds. However, some analysts maintain a Buy rating, viewing the company as a long-term growth story.
